Eribulin Not Superior to Capecitabine for Previously Treated Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Clinical Oncology, researchers have found that eribulin mesylate is not superior to capecitabine for the treatment of patients with locally advanced or metastatic breast cancer who were previously treated with an anthracycline and a taxane.

In this open label, phase 3 study, researchers sought to compare the efficacy of eribulin mesylate versus capecitabine for advanced/metastatic breast cancer.

Researchers enrolled 1,102 women with metastatic breast cancer who had previously received anthracycline- and taxane-based therapy and randomly assigned them to receive either eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced disease.

Results showed median overall survival times of 15.9 months and 14.5 months for eribulin and capecitabine, respectively (HR = 0.88; 95% CI: 0.77 - 1.00; P = 0.056). Median progression-free survival times were 4.1 months for the eribulin arm and 4.2 months for the capecitabine arm (HR = 1.08; 95% CI: 0.93 - 1.25; P = 0.30). 

In addition, the eribulin group had an 11.0% objective response rate compared with 11.5% in the capecitabine group. Researchers also found that both treatments had manageable safety profiles.

HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.
Eribulin mesylate is not superior to capecitabine for the treatment of locally advanced or metastatic breast cancer.
This phase III randomized trial ( identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs